Our team has decades of experience discovering, optimizing, and developing antibodies against complex and challenging targets.
Twist Biopharma is committed to helping you realize the potential of your biggest biologic development
programs. Wherever you are in the development pipeline, we have a solution that will elevate you to the
next level of discovery
AI and machine learning algorithms are providing more accurate in silico models of the complexities of antibody-antigen interactions. When paired with Twist’s DNA synthesis, antibody expression, and functional characterization capabilities, the chances of discovering a potent and selective antibody are greatly increased.
See how our partnerships with EVQLV and Schrӧdinger are refining antibody drug discovery.
Our experienced scientific team is led by CSO, Dr. Aaron Sato, Ph.D., a proven leader in the antibody therapeutics space. Over the multiple decades he’s spent in the biologics industry, he’s guided the discovery and development of first-in-class biologics, through IND filing.
Many drug targets, such as GPCRs, have been labeled as undruggable. Our best-in-class discovery platform, optimization capabilities, and high-throughput developability workflow was designed to uncover lead antibodies against several hard-to-drug targets, including GLP-1R, ADORA2A, and more.
Our team has decades of experience discovering, optimizing, and developing antibodies against complex and challenging targets.
Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.
| MOLCURE Inc. | Read Press Release |
| SomaLogic | Read Press Release |
| Takeda | Read Press Release |
| Vanderbilt University | Read Press Release |
| Pandion Therapeutics | Read Press Release |
| Invetx | Read Press Release |
| Seismic Bio | Read Press Release |
| Neogene Therapeutics | Read Press Release |
| Kyowa-Kirin | Read Press Release |
| Bayers | Read Press Release |
| Ono Pharmaceutical | Read Press Release |
| IMIDomics | Read Press Release |
Twist Bioscience HQ
681 Gateway Blvd
South San Francisco, CA 94080
Genes
Oligo Pools
NGS
Variant Libraries
Synthetic Controls
Antibody Discovery
IVDR Solutions
_4.svg)
_3_0.svg)
Poster
Product Sheet
Brochure